Insulin degludec and glargine U300 have been shown to be associated with a lower risk of hypoglycaemia, at equivalent glycaemic control compared with glargine U100 in individuals with type 2 diabetes [9–20]. This evidence concerns the gene INS and type 2 diabetes mellitus.